No products in the cart.
Pre-made Amivantamab benchmark antibody ( Bispecific mAb, anti-EGFR;MET therapeutic antibody, Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2;AUTS9/DFNB97/HGFR/RCCP2/c-Met Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-021
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Amivantamab biosimilar, Bispecific mAb, Anti-EGFR;MET Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2;AUTS9/DFNB97/HGFR/RCCP2/c-Met therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Amivantamab, sold under the brand name Rybrevant, is a monoclonal antibody medication used to treat non-small cell lung cancer.
| Products Name (INN Index) | Pre-Made Amivantamab biosimilar, Bispecific mAb, Anti-EGFR;MET Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2;AUTS9/DFNB97/HGFR/RCCP2/c-Met therapeutic antibody |
|---|---|
| INN Name | Amivantamab |
| Target | EGFR,MET |
| Format | Bispecific mAb |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa,Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None;6wvz:HL |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | Genmab,Janssen Research & Development |
| Conditions Approved | Non-small cell lung cancer |
| Conditions Active | Gastic cancer,Oesophageal cancer,Solid tumours |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | EGFR,MET |
| Package |
Previous slide
Next slide
